News

Androgen deprivation should be continued indefinitely in men with metastatic castration-resistant prostate cancer

Publish date: September 11, 2014

 

FROM THE JOURNAL OF CLINICAL ONCOLOGY

References

Members of the panel reported consultancy or advisory roles and funding from numerous pharmaceutical companies.

dbrunk@frontlinemedcom.com

On Twitter @dougbrunk

Pages

Recommended Reading

Testicular tumors increasing in Hispanic teens and young adults
MDedge Hematology and Oncology
Specialists drive overtreatment of low-risk prostate cancer
MDedge Hematology and Oncology
Encouraging data at ASCO 2014 for survival and fertility in some cancers
MDedge Hematology and Oncology
The Medical Roundtable: Prostate-Specific Antigen Screening for Prostate Cancer: Yes, No, or Maybe?
MDedge Hematology and Oncology
FDA panel recommends against approval of ultrasound therapy for early prostate cancer
MDedge Hematology and Oncology
Robot-assisted radical cystectomy doesn’t cut complications
MDedge Hematology and Oncology
ESMO updates practice guidelines for bladder cancer
MDedge Hematology and Oncology
PSA density predicts progression of low-risk prostate cancer during active surveillance
MDedge Hematology and Oncology
Effects of exercise on disablement process model outcomes in prostate cancer patients undergoing androgen deprivation therapy
MDedge Hematology and Oncology
Blood marker may signal enzalutamide, abiraterone resistance
MDedge Hematology and Oncology